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The  immune  system  is  a network  of  specialized  cell  types  and  tissues  that  communicates  via  cytokines
and  direct  contact,  to orchestrate  speciﬁc  types  of defensive  responses.  Until  recently,  we  could  only  study
immune responses  in  a piecemeal,  highly  focused  fashion,  on  major  components  like  antibodies  to the
pathogen.  But recent  advances  in  technology  and  in our understanding  of  the  many  components  of  the
system,  innate  and  adaptive,  have  made  possible  a broader  approach,  where  both  the multiple  responding
cells  and cytokines  in  the  blood  are  measured.  This  systems  immunology  approach  to  a  vaccine  responseaccinology
omputational immunology
egularization
eature selection
lastic net
uman immunology
or  an  infection  gives  us  a  more  holistic  picture  of the  different  parts  of  the  immune  system  that  are
mobilized  and  should  allow  us  a  much  better  understanding  of the  pathways  and  mechanisms  of such
responses,  as  well  as  to predict  vaccine  efﬁcacy  in different  populations  well  in advance  of  efﬁcacy  studies.
Here  we summarize  the  different  technologies  and  methods  and  discuss  how they  can  inform  us  about
the  differences  between  diseases  and  vaccines,  and  how  they  can greatly  accelerate  vaccine  development.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).. Introduction
The immune system is a complex adaptive system with emer-
ent properties such as memory and self-regulation. Its complexity
an be exempliﬁed at the network level, lymphocyte receptor
iversity, clonotype selection, cell migration, cell–cell interaction
nside immunological tissues and long-distance communication via
uid dissemination throughout the body, homeostatic regulation
nd adaptation to changing environments. The net functionality
f a healthy immune system likely depends upon the interac-
ion between immune system components at the molecular level
nd considerable integration and regulation at the system level.
herefore, as in any complex system, it is likely that immune sys-
em function cannot be predicted from the behavior of any of
ts parts separately but rather, is context dependent and hard-
ired in dynamic and functional networks involving hundreds of
omponents. Nevertheless, our current knowledge of immunol-
gy has been built for many years using a relatively deterministic
nd reductionist approach, as was necessary given our relative
∗ Corresponding author at: 279 Campus Drive, B219 Beckman Center, Stanford,
A  94305, United States. Tel.: +1 650 725 4755; fax: +1 650 498 7771.
E-mail address: mmdavis@stanford.edu (M.M.  Davis).
ttp://dx.doi.org/10.1016/j.vaccine.2015.06.117
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uignorance of the many components that have only recently come to
light. However, examples where the same cell or soluble cell prod-
uct exert distinct and even opposing functions depending on the
site of the immune reaction and the presence of other immune con-
stituents are abundant. Thus, the robust functioning of the immune
system likely relies on a highly complex multi-level interaction
network, linking intracellular biochemical networks, intercellu-
lar communication networks and inter-organ cellular trafﬁcking
networks through space and time. In addition, for obvious eth-
ical and practical reasons, we have utilized model antigens and
largely relied on mouse models of health and disease, which while
extremely useful for deciphering the cellular and molecular bases
of many immune responses, are rarely predictive of human vaccine
results. There are a number of possible explanations for this dis-
crepancy, evolution being one, with an estimated 65 million years
separating humans from mice [1] and second possibility being that
mice are kept in a relatively sterile environment, whereas cage-
free humans are exposed to a much broader range of pathogens
over their (much longer) lifespan. A third factor is that the whole
inbred mouse strains are homozygous at all their alleles whereas
humans rarely if ever are.
Recent years have seen the emergence of ‘systems biology’
approaches that are now applicable to human studies [2,3]. Ini-
tially using gene expression analysis of white blood cells from
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Multi-level high-throughput analysis of the human immune system. Com-
prehensive immune proﬁling involves multiple technological platforms that allow
us  to capture and observe an important portion of the immune response. Peripheral
blood is used to survey the perturbations in the immune system through a suite of
available techniques including next-generation sequencing (NGS); gene and protein
microarrays; multiparameter ﬂow cytometry and mass cytometry (CyTOF); multi-
plex  cytokine and chemokine analysis by Luminex and Mesoscale, and metabolomics
that relies on major recent improvements in mass spectrometry now capable
of  resolving close to a thousand metabolites. This human-centered approach to
immunology promise to improve our understanding of the immune response to
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to analyze the contribution of innate immunity to vaccine efﬁcacy
and disease pathogenesis [42]. For T cells, intracellular cytokineaccination and infection.
accinated subjects [4,5], this approach has now been extended
o cover not only gene expression, but the basic components of
he entire immune system, namely the hundreds of cell types and
ubsets, and many of the cytokines and chemokines that they com-
unicate with [6] (Fig. 1). Here it should be noted that the “quanta”
f the immune system are the many specialized cells that act rela-
ively autonomously. T lymphocytes for example, can detect even
 single molecule of a peptide antigen bound to an MHC  molecule
7–9] and then act on that information by releasing cytokines in
he case of CD4+ cells [10]. Advances in DNA sequencing tech-
ology also make it possible to analyze the immunoglobulin (Ig)
nd T-cell receptor (TCR) repertoires responding to vaccines in
reat detail [11–13] and to do this on a single cell level as well
14,15]. It is also possible to obtain the exact DNA sequence of
he whole genome in single individuals, the information about the
enes that are expressed in a particular cell state, and the compo-
ition of hundreds of different metabolites from different tissues
hat provide extremely valuable information about a particular
etabolic status in health and disease states (Fig. 1). This ability to
enerate high-throughput and high bandwidth data has co-evolved
ith technological advances in informatics to enable the generation
f integrative models of the human immune response. This systems
iology approach applied to infection and vaccination using peo-
le as a model is accelerating and will continue to accelerate our
nderstanding of how the immune system works in humans, rep-
esenting a necessary step to advance our basic understanding of
mmune system dysregulation and to enable future translational
pplications based on these basic ﬁndings. In this review paper,
e discuss some of the most important technological advances
o probe the immune system and the computational tools used
o extract relevant biological information that can be used to gain
echanistic insights and/or to identify immune biomarkers.e 33 (2015) 5271–5281
2. Genes expressed in immune cells prior to (predictive of
outcome) or in response to immune perturbation
(microarray and RNA sequencing)
One of the most successful technologies originated from avail-
able genetic information generated by the Human Genome Project,
is the gene expression microarray. Because this technology gen-
erates large amounts of expression data for a relatively low price,
microarrays have gained extreme popularity during the last decade.
The technology consists in hybridizing a nucleic acid sample (tar-
get) typically onto a glass surface containing microscopic spots
with multiple identical strands of DNA that are printed by a robot,
each of it representing one gene probe. Probe-target hybridiza-
tion is typically quantiﬁed by detection of ﬂuorophore-, silver-,
or chemiluminescence-labeled targets to determine relative abun-
dance of nucleic acid sequences in the target [16]. DNA microarrays
allow for determination of genome-wide expression proﬁles and
thus, are ideally suited for generating hypotheses to gene func-
tion that can help to identify appropriate targets for vaccine and
therapeutic intervention. DNA microarrays have been used to sys-
tematically identify tumor antigens for tumor vaccine design [17];
to identify gene proﬁles or “signatures” in patients with bacterial
pneumonia [18,19] and bacterial sepsis both in adults [20] and chil-
dren [21]; in rhinovirus, respiratory syncytial virus, and inﬂuenza
A infections [22]; malaria [23] and dengue virus infections [24];
in HIV patients [25,26]; as well as in different vaccination regimes
such as inﬂuenza [27–30], yellow fever (YF) and meningococcus
[31] vaccines. The use of this technique is accelerating our under-
standing of the bases of the host immune response to pathogenic
insults and is also extending to the genetic characterization of
genetically diverse infectious pathogens associated with a given
disease.
3. Cells and biomarker proteins expressed in immune cells
prior to (predictive of outcome) or in response to immune
perturbation (ﬂow cytometry, CyTOF)
3.1. Flow cytometry
Flow cytometry is probably the most commonly used tech-
nology in immunology research. It uses antibodies coupled with
ﬂuorophores to detect speciﬁc proteins expressed intracellularly
and on the cell surface. It has been widely used for many decades
to monitor immune responses to vaccination and infection in bulk
cell populations as well as to track the phenotypic and functional
characteristics of antigen-speciﬁc cells, but it has also been largely
applied in routine clinical settings for the diagnosis, prognosis and
monitoring of disease. For example, it helps in the diagnosis and
staging of patients with a hematological diseases [32]; for the
detection of minimal residual disease (disease beyond the limit
of morphological detection using conventional microscopy) [33];
for stem cell enumeration during immunosuppressive therapies
[34]; in solid organ transplantation to evaluate T cell cross-match
[35]; to monitor changes in cell populations after cardiopulmonary
bypass surgery for the prediction of infections in risk patients [36];
in HIV for the determination of CD4+ T cell counts [37]; to pre-
dict hemolytic disease [38]; in primary [39] and secondary [40]
immunodeﬁciencies; and largely used in blood transfusion [41].
The immunogenicity of vaccination and infection, and direct
monitoring of the innate and adaptive immune responses can be
measured by different methodologies. Flow cytometry can be usedstaining (ICS) assays have proven to be useful to measure T-cell
immunogenicity and there are numerous examples in the literature
Vaccin
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43–46]. Despite the fact that the T cell response to vaccination and
nfection has been widely studied, there is no robust T cell mea-
ure that correlates with vaccine-induced protection. For example,
n HIV vaccine was shown to be highly immunogenic as measured
y ICS, yet was not effective [47]. Additional measures for the T
ell response include the assessment of cytotoxic potential, which
an be achieved by measuring degranulation and granule contents
n speciﬁc T cell subsets. Degranulation indicates cytotoxic poten-
ial and is typically measured by the expression of CD107a on the
ell surface. This protein is normally expressed in internal granular
embranes and is transiently expressed on the cell surface during
egranulation [48]. Broader antibody panels such as those covering
he analysis of multiple cytokines, cell surface markers, and other
unctional markers such as perforin, CD107a, and CD154 with up
o 10-color resolution have also been presented [49]. For the CD4+
 cell response, assessment of helper capacity by measurement of
he expression of CD40 ligand is also common.
Several studies have analyzed the characteristics of antibody-
roducing B cells in the blood of vaccinated or infected individuals
y ﬂow cytometry. B cell differentiation into plasmablasts (PB) is
ost commonly monitored with the surface markers CD19, CD20,
D27, CD38, and CD138. The term “acute plasmablast” is often used
o associate the CD19low CD20− CD27high CD38high CD138+/− cell
opulation appearing after infection with the acute phase of the
mmune response and to differentiate them from steady-state plas-
ablasts [50]. The timing of acute PB appearance in the blood is
onsistent after immunization or infection with numerous studies
howing that after vaccination with yellow fever vaccine (YF-17D)
4], inactivated inﬂuenza vaccine (TIV) [51–55], tetanus vaccine
56,57] and after infection with respiratory syncytial virus (RSV)
57] or dengue virus [58,59] PB numbers peak consistently at day
 or 7 for recall responses and somewhat later ∼day 10 for new
esponses [53,59]. Speciﬁc T cells are also circulating within that
ime frame, and this general principal also applies to at least some
orms of autoimmunity, particularly celiac disease, where it has
een shown that gluten speciﬁc CD4+ T cells appear in the circu-
ation six days post-gluten challenge [60] as well as other types
f T cells [61]. This is a very fortunate circumstance for human
ork, since it means that a suitably timed blood sample can cap-
ure a population of lymphocytes highly enriched for cells speciﬁc
or the antigenic stimulus (in the case of PB) [53] estimated that
0–80% were speciﬁc for the immunizing ﬂu vaccine 6 days post-
accination. This spike in speciﬁc PB in the blood after vaccination
r gluten challenge, in the case of celiacs, is transient-down to base-
ine at 10+ days, whereas the duration of the response to infection
epends on the persistence of the antigen. For example, after infec-
ion with inﬂuenza or dengue the PB numbers decreases to baseline
evel within 2–3 weeks after the onset of disease [58,59] whereas in
SV-infected patients, circulating PBs are produced as long as the
irus is actively shed from infected cells [62].
.2. Cytometry by time-of-ﬂight (CyTOF)
The recently developed mass cytometer CyTOF instrument com-
ines the advantages of single-cell analysis in ﬂow cytometry with
he ability to resolve approximately 45 metal probes with min-
mal signal overlap because the signals are detected as discrete
ine spectra in mass spectroscopy, with a clear separation between
abels differing by only 1 Da in molecular weight. This enables an
xponential leap in the amount of data collected and has revealed
reviously unknown complexities in lymphoid populations.
This technology has been utilized to track the signaling behaviorf different cell subsets spanning deﬁned hematopoietic hierar-
hies [63]; to characterize the phenotypical and functional status
f T cells speciﬁc for CMV, EBV and inﬂuenza in combination with
HC-tetramer staining [64]; to monitor cellular states in responsee 33 (2015) 5271–5281 5273
to multiple drugs [65]; to detect speciﬁc cell cycle phases of differ-
ent immune cells [66]; to characterize the T cell response against
over 100 epitopes [67]; to monitor antigen-speciﬁc CD8+  and
 T cells in celiac disease [61]; to study the diversity of NK
cells in humans [68,69]; to ﬁnd the levels of antigen required
to activate versus inhibit signaling cascades [70]; to characterize
antiviral immunity to heterologous prime-boost vaccination strate-
gies against hepatitis C virus [71]; to investigate varicella-zoster
virus (VZV) infection of tonsil T cells [72]; to compare signaling
pathway activation and cytokine production between the split
inﬂuenza vaccine and a prototypical TLR response ex vivo [73]; to
characterize signaling network relationships in CD4+ T cells [74];
to identify phenotypic and functional immune responses to sur-
gical trauma [75]; to better characterize the mucosal-associated
invariant T (MAIT) cells [76]; to better understand the human B
cell lymphopoiesis [77]; and more recently, in a study on twins, to
decouple the effects of genetics versus environment in the com-
position of dozens of immune cells, among many other variables
including the response to inﬂuenza vaccination [78]. Many of these
data sets have been deposited in publicly available databases (for
example, the Immunology Database and Analysis Portal, ImmPort).
The CyTOF instrument is a promising technology with huge
advantages over common ﬂow cytometry, especially for the iden-
tiﬁcation of new cellular functions and cell markers important in
the response to infection and vaccination. It is particularly suited to
situations where the sample material is limited, such as pediatric
samples, as only a few million PBMCs can yield a very comprehen-
sive dataset [79] (Sigal et al., unpublished).
4. Immunoglobulin and T cell receptor repertoire analysis
(Next Generation Sequencing)
Recent advances in nucleic acid sequencing have allowed the
determination of the diversity and clonal expansion of respon-
ding Ig and TCR sequences in astonishing numbers and depth-
with hundreds of thousands to millions of “reads” becoming com-
mon with the most advanced instruments. These “Next Generation
Sequencing” (NGS) methodologies started with the breakthrough
454 instruments from Roche (introduced in the year 2004) but
then has advanced to more high throughput instruments such as
LifeTechnologies Ion Torrent and the Illumina MiSeq and HiSeq.
These two technologies employ similar base methodology that
includes template preparation, sequencing and imaging, and data
analysis [80]. The process starts with the construction of a library
of nucleic acids (DNA or complementary DNA (cDNA)) off of which
new DNA fragments are synthesized. Then the sequencing occurs
through a cycle of washing and ﬂooding the fragments in a sequen-
tial order; as nucleotides incorporate into the growing DNA strand,
they are digitally recorded as sequence. The PGM and the MiSeq
each rely on a slightly different mechanism for detecting nucleotide
sequence information. The PGM depends on the detection of pH
changes (semiconductor sequencing) induced by the release of a
hydrogen ion when the nucleotide is incorporated into a growing
strand of DNA [81]. By contrast, the MiSeq relies on the detec-
tion of ﬂuorescence generated by the incorporation of ﬂuorescently
labeled nucleotides into the growing strand of DNA. NGS performs
massively parallel sequencing, during which millions or billions of
DNA fragments from unique samples can be sequenced, minimizing
the need for the fragment-cloning methods used in Sanger sequenc-
ing, thus facilitating high-throughput sequencing, which allows an
entire genome to be sequenced in less than 1 day. NGS enables a
very broad approach to Ig or TCR repertoire analysis. The applica-
tions of NGS are multiple but for the purpose of this review we
highlight only those that pertain to immune variability, vaccino-
logy and infection. NGS has been used to identify genetic variants
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ssociated with immune cell phenotypes in healthy individuals and
atients with autoimmune disease [82], as well as to study, in new-
orns, the variability in cytokine and chemokine expression, key
oluble factors that regulate immune responsiveness [83]. It was
lso applied to characterize the diversity of human B cell or T cell
epertoires in cases of HIV [84], inﬂuenza vaccination [11,12,85],
 cell development [86], and in the context of common infections
uch as cytomegalovirus (CMV) and Epstein–Barr virus (EBV) [87].
otable discoveries thus far are the observation of limited reper-
oires in the vaccine response repertoire of aging adults versus
ounger subjects [88], the presence of memory CD4(+) T cells spe-
iﬁc to viral antigens in healthy adults who had never been exposed
154], and also the presence of clonal expansions unrelated to the
accine responses, which correlate with a latent EBV infection [87].
 similar phenomenon has been seen in aging mice with respect to
he TCR repertoire [89].
Also interesting and important is the observation of convergent
ntibody heavy chain sequences, especially in the CDR3 region, in
t least some responses, such as Dengue infection and inﬂuenza
accination [11,90]. These seem to occur in many although not
ll individuals, and suggest that there might be a useful uni-
ormity in these responses detectable in bulk sequencing data
lone.
A relatively new development in the use of NGS is its application
n single T or plasmablast cells responding to a vaccine or infection
14,15]. Here, individual cells of the desired type are sorted into
eparate wells, lysed and the TCR or Ig chains ampliﬁed, with or
ithout other genes of interest (such as cytokines or transcription
actors in the case of T cells). After the ampliﬁcation, all products
rom a given cell are ligated with a unique nucleic acid sequence
barcode” and then all the products are combined and sequenced
n masse.  The barcode enables all the products of each cell to be re-
rouped informatically, and thus a complete heavy and light chain
orm a plasmablast, or alpha and beta TCRs from a T cell can be
econstructed and used to determine the speciﬁcity and/or afﬁnity
f an antibody [91] or the speciﬁcity and phenotype of a T cell [15].
hese methods allow one to go quickly from an immune response
bout which little or nothing is known.
A more recent and promising development of NGS is its applica-
ion to epigenetic proﬁling. For example, a fast and highly sensitive
ethod was developed based on direct in vitro transposition of
equencing adaptors into native chromatin by the bacterial enzyme
ransposase, which inserts only in regions of open chromatin,
hereby generating sequencing-library fragments that can be PCR-
mpliﬁed. Thus, ampliﬁable DNA fragments suitable for NGS are
referentially generated at locations of open chromatin allowing
hole-genome proﬁling of active chromatin sites [92]. Although
his technology has not yet been used in human immunology stud-
es, it is important to note its great potential use in vaccination and
nfection settings.
Thus, NGS is rapidly becoming a core technology in vaccine anal-
sis [93], which ultimate goal is to identify the pathways by which
athogens activate protective immune responses and potentially
nhance those responses by vaccinating people based on iden-
iﬁed genetic signatures predictive of both immunogenicity and
afety.
. Proteins produced prior to (predictive of outcome) or in
esponse to immune perturbation
.1. Antibody proﬁling (protein and peptide microarrays).1.1. Protein microarrays
Molecular proﬁling at the protein level offers a rapid and high-
hroughput systems approach to scientiﬁc discovery comparede 33 (2015) 5271–5281
to traditional single-protein or single-pathway studies. Emerging
technologies providing global proﬁling represent exciting oppor-
tunities for the biomedical research community.
Recently, protein microarrays comprised of cell lysates, anti-
gen fractions, or highly puriﬁed proteins have been successfully
used to proﬁle serum antibody levels in various diseases [94–96].
The discovery of antibodies in different settings of vaccination and
infection is one important aim in proteomic systems biology, and
is a critical step for enabling personalized medicine.
Construction of protein arrays is similar to DNA microarrays,
except that the immobilized species is a protein and the array often
represents only partially the entire proteome. Several approaches
for tracking immune responses have been undertaken using these
technologies. For example, it has been used for the discovery of
schistosomiasis vaccine antigens in chronically infected individuals
[97]; to identify immunogenic Plasmodium vivax proteins in malaria
patients [98]; in the identiﬁcation of proﬁles that can distinguish
Helicobacter pylori-seropositive and seronegative cancer patients
[99]; to deﬁne immunodominant proteins within the Salmonella
typhi membrane in Bangladeshis infected with acute typhoid
[100]; to evaluate serum from autoimmune and immunodeﬁcient
patients for antibodies against cytokines, chemokines, and growth
factors in systemic lupus erythematous (SLE) [101]; to identify con-
served and polymorphic linear B-cell epitopes of Trypanozoma cruzi
in Chagas disease [102]; and to characterize the antibody proﬁles
elicited by smallpox vaccines [103] with follow-up studies involv-
ing the sera from more than 2000 smallpox-vaccinated humans
[104].
Protein arrays have been also used to assess host antibody
proﬁles in response to infection with Brucella melitensis [105],
Burkholderia pseudomallei [106], Vaccinia virus [107] and Coxiella
burnetii [108]. The use of protein microarrays has also aided the
identiﬁcation of different antibody isotype proﬁles for differenti-
ating acute versus chronic Q-fever [109]. In addition to antibody
proﬁling, protein microarrays can be used to identify antigens for
diagnostic tools, and candidate antigens for vaccine development
[109].
5.1.2. Peptide microarrays
A peptide array is a collection of peptides presented on a solid
surface, usually made of glass or plastic. The assay principle is sim-
ilar to an ELISA in that a biological sample is incubated and the
presence of antibodies recognizing speciﬁc epitopes is detected.
The peptides are typically linked to the surface of a chip, the shape
of a microscope slide. This array is directly incubated with differ-
ent biological samples like puriﬁed antibodies, patient or animal
sera, cell lysates and cell supernatants, etc. After washing, a sec-
ondary antibody often tagged by a ﬂuorescence label can then
be detected by a ﬂuorescence scanner. However, other detection
methods such as chemiluminescence, colorimetric or autoradiog-
raphy also exist.
Clinical applications of peptide arrays are biomarker discovery,
proﬁling of serological responses of patients during infection or
vaccination, monitoring clinical interventions, and development
of diagnostic tools and vaccines. Peptide arrays were successfully
used in the identiﬁcation of speciﬁc epitopes on Toxoplasma gondii
antigens, leading to an improvement in the serological diagnosis of
toxoplasmosis [110]; to study the antibody diversity against linear
HIV-1 sequences in HIV-1-infected humans and HIV-1-vaccinated
humans [111]; to proﬁle the pre-existing antibody repertoire to the
seasonal inﬂuenza vaccine thus enabling to distinguish immune
from pre-immune samples in young and older donors [6,112,113];
in Valley Fever patients [114]; to identify linear B epitopes of per-
tactin of Bordetella pertussis induced by immunization with whole
and acellular vaccine in mice [115]; and to identify strain-speciﬁc
B-cell epitopes in T. cruzi [102]. More recently photolithography
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as used to synthesize arrays (Intel arrays) that contained every
ossible overlapping peptide within a linear protein sequence
overing the N-terminal tail of human histone H2B individuals with
LE [116]. Such new methods provide powerful tools for rapid and
ccurate measurement of broad antibody-based immune responses
hat may  be extremely useful in measuring response to vaccines
nd infectious agents.
.2. Cytokines and chemokines (Luminex, MSD)
Cytokines and chemokines are soluble proteins secreted by
mmune cells that enable passage of information between immune
ells and participate in cell activation, cell growth, migration, and
ifferentiation. They are a large part of the grammar of the immune
ystem, that is, the way it talks to itself and orchestrates an immune
esponse or the resolution of a response. Cell–cell interaction is
lso import, but here as well, the message is often conveyed by
articular cytokines.
Several technologies have been developed for multiplexing the
nalysis of cytokines and chemokines. Probably the most popu-
ar ones with the capability to measure several dozens of analytes
re the xMap Luminex and the MesoScale Discovery (MSD) plat-
orms. In the xMAP technology, microbeads are color-coded into
00 distinct sets each of which can be coated with a reagent spe-
iﬁc for a particular assay. A light source then excites the internal
yes that identify each microsphere particle with many readings
ade on each bead set, which validate the results. This technology
hares common components with general ﬂow cytometry instru-
ents such as lasers, ﬂuidics, and optics. Using this process, the
MAP Technology allows multiplexing of up to 500 unique bioas-
ays within a single sample. In contrast, the MesoScale Discovery
MSD) platform is similar to a multiplexed ELISA. Individual spots
n a microtiter plate are coated with capture reagents for the
nalytes of interest, which are then detected with enzyme-linked
etector antibodies. An electrochemiluminescent substrate is then
sed to create a light signal that is quantitated by the instrument.
dvantages of this detection system include high sensitivity and a
ide dynamic range, as well as minimal interference from matrix
actors.
Studies addressing the changes in cytokine proﬁles upon immu-
ization or infection are abundant. For example, these technologies
ave been used to determine the systemic cytokine pattern induced
y vaccination with human papillomavirus (HPV) L1 virus-like par-
icles (VLP) [117]; to evaluate the potential of cytokines present in
lasma from patients with dengue in stratifying disease severity
118]; as potential biomarkers that differentiate healthy contacts
rom tuberculosis patients [119]; to investigate the responses to
ycobacterium tuberculosis puriﬁed protein derivative (PPD) in
amples from BCG-vaccinated or -unvaccinated infants [120]; dur-
ng inﬂuenza vaccination of patients undergoing tonsillectomy
121] or to compare cytokine production upon BCG vaccination in
alawian infants compared with UK infants [122]. In one study
onsisting of 141 healthy infants who had been immunized with
epatitis B vaccine (HBV), single-nucleotide polymorphisms in
enes encoding for cytokines and cytokine receptors were investi-
ated for their associations with variations in the immune response
o vaccination [123]. Multiplex cytokine assays have been also used
n the characterization of the CD4+ T cell response to YF-17D vac-
ine [124]; to evaluate innate and adaptive immune responses to
ut bacteria in HIV patients [125]; to study the effect of CMV  in
ytokine changes during cycling time trial in athletes [126]; to
tudy the inﬂammatory response to TIV among pregnant women
127]; to ﬁnd biomarkers of inﬂammation associated with mortal-
ty and hepatitis ﬂares in persons coinfected with HIV and Hepatitis
iruses [128]; and to determine the cytokine response to synthetice 33 (2015) 5271–5281 5275
double-stranded RNA, as an agonist for toll-like receptor (TLR) 3
[129].
In summary, there are now excellent methods for assaying many
cytokines at once in serum samples-up to 63 here in Stanford’s
Human Immune Monitoring Center, and probably many more in
the future. This kind of data particularly combined with cell subset
analysis and some of the other technologies described here, begin
to capture a good portion of an individuals’ immune system, and
thus enable comprehensive immune monitoring.
6. Cellular metabolic states predictive of outcome and
changes in cell metabolism in response to immune
perturbation (metabolomics)
Metabolomics is the systematic measurement of small-
molecule metabolite proﬁle within a biological sample, such as
urine, plasma or tissue. Surveying these small molecules allows for
better understanding of an organism’s phenotype and metabolism,
and is a central hub for the inﬂuences of genes, microbiota and
environmental inﬂuences.
There are two  approaches in metabolomics: targeted
metabolomics and untargeted metabolomics or metabolic proﬁl-
ing. In targeted metabolomics deﬁned sets of structurally known
and biochemically annotated metabolites are quantiﬁed, and is
based on a previous understanding of biochemical pathways.
One major advantage of targeted metabolomics is that it gen-
erally provides information about the molecular concentrations
of metabolites involved in a pathway, which facilitates the
immediate understanding of deviations from normal. Another
advantage is that interpretation of targeted metabolomics data
is straightforward. In contrast, untargeted metabolomics is the
comprehensive analysis of all the measurable analytes in a sample
including chemical unknowns. Many have recognized untargeted
metabolomics as having unprecedented value to bringing clarity
to complex “omics” data. The reason for this is that metabolites
are a proxy to the phenotype and the metabolome is the very end
product of the genetic setup of an organism, as well as the sum
of all inﬂuences it is exposed to, such as nutrition, environmental
factors, or treatment. Untargeted metabolomics includes analysis
of large arrays of metabolites, thereby extracting biochemical
information that reﬂects functional endpoints of biological events.
In addition, metabolomics can serve as a diagnostic source of data
for understanding the underpinnings of a particular phenotypic
state whether that change is induced by a vaccine or an infectious
agent.
In a metabolomics experiment, samples are subjected to
methanol extraction and split into aliquots for analysis by
ultrahigh performance liquid chromatography/mass spectrometry
(UHPLC/MS) in the positive, negative or polar ion mode and by
gas chromatography/mass spectrometry (GC/MS). Metabolites are
identiﬁed by automated comparison of ion features to a reference
library of chemical standards followed by visual inspection for qual-
ity control.
Metabolomics has been used as a tool for discovery of
metabolic signature to distinguish sepsis from systemic inﬂam-
matory response syndrome in humans [130]; to proﬁle cellular
responses upon infection with Hepatitis C Virus [131]; to ﬁnd
biomarkers patients infected with tuberculosis (TB) [132] as well
as to deﬁne metabolic networks in TB [133]. In addition, it has
demonstrated potential for identiﬁcation of biomarkers for disease
subtype, stage and treatment response, as well as insight into the
molecular basis of diseases. At the biochemical level, inﬂammatory
mediators and biomarkers are represented by metabolites includ-
ing lipids/fatty acids, amino acids, anti-oxidants and nucleotides
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hat report on key aspects of inﬂammation including cell trafﬁcking,
ell activation, oxidative stress and signaling.
Metabolomics signatures have been identiﬁed for prediction
f death in septic patients [134]; and important metabolites
ere discovered in gum infections (periodontal disease) [135].
etabolomics has been also used to distinguish patients with pneu-
onia from those suffering from sepsis [136]; and more recently,
or the identiﬁcation of important metabolites for Vaccinia virus
eplication [137].
The global analysis of soluble metabolites is starting to yield
mportant insights with respect to the variability in the immune
esponse in humans. In addition, these measurements enable the
dentiﬁcation of biomarkers that can be used to distinguish patients
nfected with different pathogens and with various degrees of clin-
cal presentations. Therefore, these technologies provide us with
ata that are potentially quite useful to understand immunity in
umans.
. From data to function: making sense of the complexity
Generating large amounts of data encompassing multiple “lay-
rs” of the immune system is now straightforward and has been
reatly facilitated by the creation at Stanford of a Human Immune
onitoring Core facility able to conduct deep immune proﬁl-
ng of human blood and other clinical samples [2]. This facility
llows analysis protocols to be standardized and broadly applied
cross many studies, achieving economies of scale (much as the
uman genome project drove up sequencing throughput and drove
own the cost). It also frees research personnel to pursue spe-
iﬁc questions and analyses using the data provided by the facility.
n particular, researchers are constantly looking for analytical
ools that help them analyze and guide discovery of features that
re either important mechanistically for a particular condition or
utcome, and/or to identify biomarkers. The identiﬁcation of pre-
ictors for a particular immunological and/or clinical outcome is
he most common scenario in systems immunology. These types
f associations fall into the category of supervised learning that
ontrasts with unsupervised learning, in which a suite of method-
logies are available to identify hidden structure in data when the
utcome is inexistent or unknown.
The most common types of associations are those between
mmune features (e.g. immune genes, cytokines, cell subsets,
etabolites) and standard outcome variable of clinical importance
e.g. infected versus uninfected; responders versus non-responders
o vaccination; treated versus untreated condition, etc.), and bioin-
ormatics is key to this process with many hundreds of tools
vailable. Important biological insights are emerging from these
ystems immunology approaches to vaccination and infection. For
xample, the role apoptosis [6], lipid metabolism and endocrine
actors [29], the microbiome [138] and nutritional sensing path-
ays [139] on promoting vaccine-induced immunity have been
eported.
The steps involved in this discovery adventure involve data
rocessing and standardization, feature or variable selection,
nd functional annotation (interpretation of results). Below we
ostly focus on feature selection since the downstream anal-
ses and biological insights that can be drawn depend upon
he variables that are discovered by a given computational
odel.
In feature selection, relevant parameters (subset of predictors)
re discovered using appropriate statistical models. In order to be
ble to generalize an observation, that is, to ﬁnd real associations
etween immune variables and a given outcome that are likely to be
ound in different data sets – encompassing diverse human popu-
ations – regularization methods are often used. In statistics ande 33 (2015) 5271–5281
machine learning, regularization methods are used for model selec-
tion, in particular to prevent overﬁtting by penalizing models with
extreme parameter values (see below).
Common questions in systems immunology involve contin-
uous or binary outcomes, which can be solved using multiple
linear regression, logistic regression, Cox partial likelihood, and
others statistical procedures. To select an appropriate model that
best explains the data using a relatively small number of predic-
tors, commonly used statistical procedures involve model selection
approaches based on Akaike Information Criteria, Bayesian Infor-
mation Criteria, etc. Such model selection techniques are necessary
since modern data sets require high-dimensional modeling often
with many thousands of predictor variables such as in whole-
genome gene expression microarrays (see above) and small
number of observations and under these circumstances regres-
sion methods can overﬁt. In simple terms, overﬁtting refers to
the propensity of models to capture noise in the data at the
expense of a genuine relationship. In such cases, the set of iden-
tiﬁed predictors will likely fail to generalize to additional data
sets. A regularization method imposes mathematical constraints
on the regression coefﬁcients in a regression analysis, encour-
aging “simpler” solutions – i.e. models with a restricted set of
predictors. Regularization methods are used for model selection
and thus, are often applied in biomarker discovery and in systems
approaches to solve immunological questions. Speciﬁcally, regu-
larization refers to tuning or selecting the preferred level of model
complexity so the model is better at generalizing. To regularize, at
least two  considerations are required: (1) testing how good the
models are at prediction, for example using cross-validation or
a validation data set and (2) a tuning parameter which enables
changing the complexity of the model. The complexity parameter
is adjusted to ﬁnd the value that gives the best model predic-
tions.
The most common regularization variants are known as l1 and
l2 regularization, which correspond to mathematical constraints
imposed on the regression coefﬁcients for each predictor vari-
able such that only the most relevant associations are identiﬁed.
As mentioned above, the purpose of this shrinkage is to prevent
overﬁtting arising due to either collinearity of the covariates or
high-dimensionality. Although both methods are shrinkage meth-
ods, the effects of l1 and l2 penalization are quite different in
practice. Applying an l2 penalty tends to result in all small but
non-zero regression coefﬁcients, whereas applying an l1 penalty
tends to result in many regression coefﬁcients shrunk exactly to
zero and a few other regression coefﬁcients with comparatively
little shrinkage. Combining l1 and l2 penalties tends to give a
result in between, with fewer regression coefﬁcients set to zero
than in a pure l1 setting, and more shrinkage of the other coef-
ﬁcients (see the Elastic net below). The amount of shrinkage is
determined by tuning parameters 1 and 2. A value of zero
always means no shrinkage and a value of inﬁnity means inﬁnite
shrinkage (= setting all regression coefﬁcients to zero). l1 penalty
can be also seen as setting a Laplacian prior on the regression
coefﬁcients – which results in a stringent penalty and sparse solu-
tions. In contrast, l2 corresponds to Gaussian prior and results in
a more permissive incorporation of features to the model since
the regression coefﬁcients are more spread across features (see
below).
7.1. Sparsity via l1
As mentioned, l1 uses the Laplace distribution which is a con-
tinuous probability distribution that can be thought of as two
exponential distributions spliced together back-to-back (see Fig. 2).
A probability distribution links each outcome of a statistical exper-
iment (in this case regression coefﬁcients) with its probability of
D. Furman, M.M. Davis / Vaccin
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Fig. 2. Laplace versus Gaussian probability distribution. The ﬁgure shows the proba-
bility (y-axis) of occurrence of a regression coefﬁcient (x-axis) with Laplace prior (l1)
(blue line) or Gaussian prior (l2) (red line). As can be observed, with l2/Gaussian as
one moves away from zero the probability for such regression coefﬁcient becomes
progressively smaller, whereas in l1/Laplace the probability of both very small and
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procedure for ﬁtting the entire Lasso or Elastic net regulariza-
tion path for linear regression, logistic and multinomial regressionarge coefﬁcients is higher than with l2/Gaussian. (For interpretation of the ref-
rences to color in this legend, the reader is referred to the web  version of the
rticle.)
ccurrence. For simplicity, let’s just consider the one-dimensional
ase where the l1 regularized loss function can be deﬁned as
(x) = f (x) + ‖x‖1
As it can be observed, l1 regularization combines a loss function
(x) and a l1 penalty; it can be inferred that F would be 0 if  is large
nough, which produces a strong regularization effect.
Practically speaking, if x is a vector, use of l1 can lead to some
omponent of optimal x being exactly zero while others may  be
elatively large (Fig. 2). The function is said to be non-smooth since
he ﬁrst derivative does not exist at x = 0. The implication of this
s that the l1 regularization provides sparse estimates. Namely, in
 high dimensional space, one obtains mostly zeros and a small
umber of non-zero coefﬁcients. This is key since it incorporates
ariable selection to the modeling problem.
A number of methods have been proposed using l1 regular-
zation. For example, the wavelet shrinkage and Basis pursuit
140,141], the Lasso [142], Least Angle Regression (LARS) [143],
omponent Selection and Smoothing (COSSO) in multivariate
onparametric regression [144], and others. Probably the most
ommonly used l1-based regularization method is the Lasso, which
s a regularized version of least squares. The method of least
quares is much applied in data ﬁtting and seeks to ﬁnd a solu-
ion that minimizes the sum of the squares of the errors made
n the results of a given model. The best ﬁt is the one that mini-
izes the sum of squared residuals, a residual being the difference
etween an observed value and the ﬁtted value provided by a
odel.
As mentioned above, in Lasso a penalty parameter is applied
uch that most of the parameters’ regression coefﬁcients are driven
o zero. This shrinkage procedure effectively culminates in the iden-
iﬁcation of a relatively small number of relevant predictors, which
reates a model with high degree of sparsity. Despite this advan-
age over other regularization methods, the Lasso suffers from
ome disadvantages or limitations when applied to immunological
uestions. For example, (1) if the number of variables (or measure-
ents) (p) is greater than the number of observations (samples)
n), which is typically the case in systems immunology problems,
he Lasso selects at most n variables, this is, the number of selected
mmune features is bounded by the number of samples. This cane 33 (2015) 5271–5281 5277
be a restricting factor if important variables exceed the sample
size, and (2) often there exist a degree of signiﬁcant correlation
between the measured variables (genes, cytokines, etc.) most fre-
quently for features sharing the same biological pathway. These
variables effectively form a group, and the Lasso fails to select for
grouped variables, as it tends to pick one variable from a set of corre-
lated ones and ignore the others. Thus, while being highly efﬁcient
and robust for feature selection, when applying the Lasso it is pos-
sible that (1) important features are ignored by the selected model
and (2) features involving common pathways and functions are not
necessarily selected in a joint fashion.
7.2. L2 regularization
l2-regularized loss function is deﬁned as:
F(x) = f (x) + ‖x‖22
In this case, the function is smooth since it can have continuous
derivatives (Fig. 2). Practically speaking, l2 regularization spreads
error throughout the vector x, and jointly shrinks the correspond-
ing coefﬁcients minimally. Least-square penalized by l22ˆ penalty is
referred to as Ridge regression.
One of the prime differences between Lasso and Ridge regres-
sion is that in Ridge regression, as the penalty is increased, all
parameters are reduced while still remaining non-zero, while in
Lasso, increasing the penalty will cause an increasing number of the
parameters to be driven to zero. Thus Lasso effectively deselects the
features from the regression. Hence, it automatically selects more
relevant features and discards the others, whereas Ridge regression
never fully discards any features.
Additional feature selection techniques are developed based on
the Lasso including Bolasso which, in addition, performs bootstrap
on samples [145] and FeaLect [146] which generates a score based
on a combination of bootstrapping procedures and the identiﬁca-
tion of the best relevance-ordering of the features for each sample.
However, an ideal algorithm for efﬁcient feature selection in sys-
tems immunology is one in which (1) variable selection is built into
the procedure and (2) automatically includes whole groups into the
model if one variable amongst them is selected.
7.3. The Elastic net regularization
The Elastic net is a regularized regression method that linearly
combines the l1 and l2 penalties of the Lasso and Ridge methods.
As mentioned previously, the Ridge penalty shrinks the coefﬁcients
of correlated predictors toward each other while the Lasso tends to
pick one of them and discard the others.
The Elastic net regularized function can be deﬁned as:
ˆˇ = arg min
ˇ
(
∥
∥y − Xˇ
∥
∥
2 + 2
∥
∥ˇ
∥
∥
2 + 1
∥
∥ˇ
∥
∥
1
)
where the l1 part of the penalty generates a sparse model, and the
quadratic part of the penalty: (1) removes the limitation on the
number of selected variables, (2) encourages “grouping effect”, or
the joint selection of correlated predictors and (3) stabilizes the l1
regularization path. As observed form the function, the Elastic net
penalty mixes both l1 and l2 penalties.
The glmnet package (R Bioconductor) is an extremely efﬁcientmodels, Poisson regression and the Cox model. With a penalty
deﬁned as:
(1 − ˛)/2
∥
∥ˇ
∥
∥
2 + ˛
∥
∥ˇ
∥
∥
1
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he Elastic net mixing parameter (alpha, ˛) can be set to 1, which
s equal to the Lasso penalty, or set to 0, which is equal to the Ridge
enalty.
Here, if predictors are correlated in groups, an  ˛ = 0.5 will tend
o select the groups in or out together (see below). This is a
igher-level parameter, and users might pick a value upfront, or
xperiment with a few different values.
Probably one of the most interesting characteristics of the glm-
et package is the ability to separate penalty factors that are applied
o each coefﬁcient (or data-type). The penalty factor allows differ-
ntial shrinkage; it can be set to 0 for a deﬁned set of variables,
hich implies no shrinkage, or 1 for a different set of variables,
hich will be penalized assuming l1 penalty.
This is extremely helpful in studies where the size for each
ata type is substantially different. For example, broad and
eep immune proﬁling [6,29,147] often involves measuring genes
xpressed in blood cells in addition to circulating cytokines,
etabolites, etc. (Fig. 1). These data sets greatly differ in size,
ith large-size data types such as whole-genome gene expression
icroarrays, which contain some 20,000 features; intermediate-
ize data types, such as broad-coverage (untargeted) metabolomics
onsisting in less than 1000 features; and small-size data types such
s multiplexed cytokine assays typically consisting in dozens of fea-
ures. These disparities can affect the feature type that is selected
ith genes having the highest likelihood and cytokines the least.
o account for this and encourage that features from different data
ypes are selected more parsimoniously, glmnet can set differen-
ial penalty factors for each data type. For example, an alpha = 0.2
pplied for cytokines will promote a Ridge penalty; alpha = 0.5
pplied for metabolites will weight Lasso and Ridge penalties to a
imilar extent, and alpha = 1 can be set for genes, which will apply
ull Lasso penalty for genes only.
The Elastic net has been used by our group and others in a
umber of studies in immunology in general, and in vaccina-
ion and infection in particular. For example, in the analyses of
ene–gene interaction in diabetic patients [148]; for deconvolv-
ng transcriptomic data in the context of acute kidney allograft
ejection [149]; to identify correlates of protection to anthrax vac-
ination in macaques [150]; to identify features able to classify
icrobial communities associated with clinical outcomes in bacte-
ial vaginosis [151,152]; for the identiﬁcation of factors associated
ith inﬂuenza infections [153] and those predicting inﬂuenza vac-
ine responsiveness [6,113].
. Concluding remarks
These are exciting times in human immunology and vaccine
ork where we are able to produce data of unprecedented scale
nd depth, spanning much of the immune system. This systems
mmunology approach is starting to provide us with a much more
lobal perspective on the complex molecular and cellular events
hat occur during an immune response. The technological break-
hroughs that have transformed genomics, epigenetics, proteomics
nd multiparameter ﬂow cytometry have also provided immu-
ologists with new tools with which to examine immunological
esponses. With the many recent vaccine failures or near failures
HIV, Dengue, TB), there is also the realization that we  have unﬁn-
shed business in the development of vaccines to the most difﬁcult
iseases, where long established methods are not working; and
o we need a better understanding of vaccines that work, to start
ith. In this review, in addition to these new technologies, we
ave also focused on data analysis; speciﬁcally regularization and
eature selection, which enable researchers to better understand
iological data collected from systems approaches. Indeed, min-
ng and interpreting high-throughput data sets remains the majore 33 (2015) 5271–5281
chellenge to understanding immunity, especially now that tech-
nologies have become robust and fairly inexpensive. Importantly,
there exist disproportionate rates with comparison of data gener-
ation with data analysis, interpretation and knowledge extraction.
This generates a bottleneck since data is produced in a much faster
way than can be analyzed. One of the reasons for this is that data
is generated almost in a completely automated fashion with lit-
tle intervention of a rather technical human work; and in contrast,
data analysis, interpretation and knowledge extraction is a much
slower process since requires thought intervention. In addition,
data analysis and interpretation is typically achieved by a team
of qualiﬁed personnel, this is, individuals with an understanding
of immunology, physiology and disease as well as those trained in
data mining and bioinformatics. To exemplify this unbalance in the
rate of data generation to knowledge extraction, in our experience,
multidimensional data that can be collected in a few months usually
takes over a year to become coherent information and be ulti-
mately interpreted to generate knowledge. For instance, a research
paper reporting results from a system biology study typically ﬁl-
ters the many thousands of hypotheses that can be drawn from
multidimensional data. Hundreds of solutions arise that are then
hierarchized by a set of parameters predeﬁned on an individuals’
own  set of values and prior knowledge. However, the published
report consists of one or two  main messages that may  or may not
be based on prior knowledge. Therefore, enormous quantities of
under-analyzed data have accumulated over the last few years,
many of which are available in public repositories, such as gene
expression omnibus (GEO), ImmPort, ArrayExpress, etc. and thus
provide fruitful substrates for subsequent and meta analyses.
More often than not, for any of our complex traits, the pheno-
type that we  observe does not come from a single factor acting
alone, but rather from a system of features that are connected to
each other and it is the output of the system that produces the
phenotype, or trait that we  are interested in. Correlating the huge
amounts of genotypic and phenotypic data generated by high-
throughput methods can create the knowledge needed to speed
development of harder and more productive immune systems; how
the immune system evolves, how it diversiﬁes, how it interacts
with other immune systems and with other entities, and how it
responds to environmental changes, so we can learn from better
adapted systems as well.
It is a fact that one can test enough different correlations and
ﬂuke results will drown out the real discoveries. Propitiously, there
are various ways to deal with this problem, which is more serious in
large data sets, because there are vastly more possible comparisons
than there are data points to compare. Without careful analysis and
the application of regularization methods such as the l1, l2 or the
Elastic net, the ratio of genuine patterns to spurious patterns – of
signal to noise – quickly tends to zero.
In summary, systems immunology represents a new approach
to the analysis of infections and vaccinations that examines how
associations between different immune components give rise to
the collective behavior of the immune system and how it interacts
with its environment.
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